RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN
(Thomson Reuters ONE) -
Milan, 1 February 2017 - Recordati S.p.A. will be hosting a meeting with the
financial community and specialized press on:
Thursday 9 February 2017 at 4 pm
Palazzo Mezzanotte
Piazza degli Affari, 6 - Milan
At the meeting Recordati's preliminary full year 2016 results will be presented
and the Group's development strategy and objectives for the period 2017-2019
will be discussed. The meeting will be held in English.
For those who are unable to attend the proceedings followed by a Q&A session
will be available via conference call. Dial-in numbers are:
Italy +39 02 8058811, toll free 800 213 858
UK +44 1 212818003, toll free 800 0156384
USA +1 718 7058794, toll free 855 2656959
France +33 170918703
Germany +49 65 255114451
Callers are invited to dial-in 10 minutes before conference time. If conference
operator assistance is required during the connection, please digit * followed
by 0.
A set of slides which will be referred to during the call will be available on
our website www.recordati.com under Investors/Company Presentations.
A recording of the conference call will be subsequently placed on the website
www.recordati.com.
Recordati, established in 1926, is an international pharmaceutical group, listed
on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271), with a total staff of around 4,000, dedicated to the research,
development, manufacturing and marketing of pharmaceuticals. Headquartered in
Milan, Italy, Recordati has operations in the main European countries, in
Russia, in other Central and Eastern European countries, in Turkey, in North
Africa, in the United States of America and in some Latin American countries.
An efficient field force of medical representatives promotes a wide range of
innovative pharmaceuticals, both proprietary and under license, in a number of
therapeutic areas including a specialized business dedicated to treatments for
rare diseases. Recordati is a partner of choice for new product licenses for its
territories. Recordati is committed to the research and development of new
specialties within the urogenital therapeutic area and of treatments for rare
diseases. Consolidated revenue for 2015 was ? 1,047.7 million, operating income
was ? 278.5 million and net income was ? 198.8 million.
For further information:
Recordati website: www.recordati.com
Investor Relations Media
Relations
Marianne Tatschke
Studio Noris Morano
(39)0248787393
(39)0276004736, (39)0276004745
e-mail: inver(at)recordati.it e-mail:
norismorano(at)studionorismorano.com
Announcement analyst presentation Feb 2017:
http://hugin.info/143644/R/2075043/780176.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RECORDATI via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.02.2017 - 09:05 Uhr
Sprache: Deutsch
News-ID 521186
Anzahl Zeichen: 3878
contact information:
Town:
MILANO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN"
steht unter der journalistisch-redaktionellen Verantwortung von
RECORDATI (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
